6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid has been researched along with 4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid in 1 studies
| Studies (6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid) | Trials (6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid) | Recent Studies (post-2010) (6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid) | Studies (4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid) | Trials (4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid) | Recent Studies (post-2010) (4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid) |
|---|---|---|---|---|---|
| 7 | 0 | 0 | 8 | 0 | 3 |
| Protein | Taxonomy | 6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid (IC50) | 4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid (IC50) |
|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 2.1 | |
| Nuclear receptor subfamily 0 group B member 2 | Homo sapiens (human) | 2.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arumugarajah, S; Bhuiyan, M; Chao, WR; Dawson, MI; Farhana, L; Fontana, JA; Fukushi, J; Han, YH; Harris, DL; Hobbs, PD; Jong, L; Liu, G; Mustelin, T; Patel, BB; Sani, BP; Schiff, LJ; Stallcup, WB; Su, Y; Tautz, L; Waleh, N; Xia, Z; Ye, M; Zhang, XK | 1 |
1 other study(ies) available for 6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid and 4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid
| Article | Year |
|---|---|
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and
Topics: Adamantane; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Cells; Humans; In Vitro Techniques; Microcirculation; Protein Tyrosine Phosphatases; Quantitative Structure-Activity Relationship; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Retinoids; Stereoisomerism | 2007 |